DALI Medical Devices

Executive Summary

DALI Medical Devices Ltd. is an Israeli med-tech company specializing in innovative injectable drug delivery systems, including safety needles, autoinjectors, and IoT-enabled syringes. Founded in 2003 and currently in the commercial stage, the company focuses on improving patient comfort and adherence for biologics, biosimilars, and generics. With a product portfolio targeting oncology, immunology, endocrinology, and chronic disease management, DALI addresses the growing demand for user-friendly and connected drug delivery solutions that enhance treatment outcomes and reduce healthcare costs. As a private company with 50–200 employees, DALI has established itself in the competitive drug delivery device market. Its IoT-enabled syringes offer real-time monitoring and data collection, positioning the company for growth in the expanding digital health sector. Key potential catalysts include the launch of next-generation connected devices, strategic partnerships with pharmaceutical companies for integrated delivery systems, and regulatory approvals for new autoinjector platforms in Europe and the US. With a focus on innovation and patient-centric design, DALI is well-positioned to capture market share in the rapidly evolving drug delivery landscape.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation IoT-enabled syringe70% success
• Q4 2026Strategic partnership with a top-10 pharmaceutical company for autoinjector platforms60% success
• Q2 2026CE mark approval for new reusable autoinjector device80% success